---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-022194"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:22:38.737407+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Erasca Q1 2023 net loss $33.2M; cash $390M; pipeline advances with Phase 3 trial plan

## Summary
- Net loss $33.2M ($0.22/share) vs $36.5M ($0.31/share) year ago; R&D $27.6M, G&A $9.4M.
- Cash, equivalents & marketable securities $389.7M at March 31, 2023, expected to fund into H2 2025.
- Pivotal Phase 3 SEACRAFT-2 trial for naporafenib in NRASm melanoma expected to initiate in H1 2024.
- FDA Fast Track Designation granted for ERAS-801 in glioblastoma; Phase 1 data expected H2 2023.
- Promoted Shannon Morris to CMO and Chandra Lovejoy to Chief Regulatory Affairs Officer in April 2023.

## SEC filing metadata
- accession: 0000950170-23-022194
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000095017023022194/0000950170-23-022194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000095017023022194/eras-20230515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-022194
- JSON: https://secwatch.observer/filing/0000950170-23-022194.json
- Plain text: https://secwatch.observer/filing/0000950170-23-022194.txt

## Key facts
- Earnings Releases
  Erasca, Inc. reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: On May 15, 2023, Erasca, Inc. announced its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761918/000095017023022194/0000950170-23-022194-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.